The Pancreatic Cancer Cohort Consortium (“PanScan”) consists of 12 prospective epidemiologic cohorts formed from the NCI Cohort Consortium. The PanScan genome-wide association study (GWAS) was conducted to study common genetic variants to identify markers of susceptibility to pancreatic cancer. In 2007, the study expanded to include eight case-control studies. The study team includes scientists from the cohorts comprising the Consortium and NCI and from the PanC4 case-control studies.
PanScan investigators have conducted three GWAS. PanScan I and II were conducted in 12 cohort studies and eight case-control studies. Investigators have completed and recently published PanScan III using incident pancreatic cancer cases and controls from 14 cohorts from the NCI Cohort Consortium, including the 10 that participated in PanScan I and II. Five newly joined cohorts, two new case-series, and one case-control study were also included. Replication was performed in samples from (a) the Pancreatic Disease Research (PANDoRA) consortium, a multi-institutional European case-control study of pancreatic cancer, (b) pancreatic cancer cases from PanScan III studies with DNA quantity that was insufficient for full GWAS, and (c) an in silico replication set of pancreatic cancer cases from Cancer and Leukemia Group B (CALGB) 80303, a U.S. cooperative group clinical trial of patients with advanced pancreatic cancer who had previously undergone genotyping.
At this time, the three PanScan consortium GWAS have led to the discovery of nine novel regions in the genome associated with risk for pancreatic adenocarcinoma at the genome-wide significant level. Additional investigations are ongoing.